<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"><channel>
<title>Biohack Health</title>
<link>https://biohackhealth.uk/</link>
<description>An educational journal covering peptide science, GLP-1 and metabolic research, recovery protocols, and the regulatory landscape.</description>
<language>en-gb</language>
<item><title>Retatrutide After Phase 3: What Four Trial Readouts Actually Showed</title><link>https://biohackhealth.uk/blog/retatrutide-after-phase-3/</link><guid>https://biohackhealth.uk/blog/retatrutide-after-phase-3/</guid><pubDate>Mon, 24 Aug 2026 23:00:00 GMT</pubDate><description>Between December 2025 and July 2026, four Phase 3 trials reported topline results. The compound moved from a promising signal to a late-stage asset with data across obesity, diabetes, and CVD.</description><category>Research</category></item>
<item><title>TB-500 and Thymosin Beta-4: Why the Fragment Isn't the Molecule</title><link>https://biohackhealth.uk/blog/tb-500-thymosin-beta-4/</link><guid>https://biohackhealth.uk/blog/tb-500-thymosin-beta-4/</guid><pubDate>Mon, 24 Aug 2026 23:00:00 GMT</pubDate><description>Most writing about TB-500 cites research about Thymosin Beta-4. Those are not the same thing, and the gap between them is the most important fact about this compound.</description><category>Research</category></item>
<item><title>Peptide Regulation in 2026: What Actually Changed</title><link>https://biohackhealth.uk/blog/peptide-regulation-2026/</link><guid>https://biohackhealth.uk/blog/peptide-regulation-2026/</guid><pubDate>Mon, 24 Aug 2026 23:00:00 GMT</pubDate><description>The regulatory landscape shifted through three separate mechanisms: a compounding decision in 2023, shortage resolutions in 2024-25, and an enforcement campaign in 2026.</description><category>News</category></item>
<item><title>Collagen Peptides: The One With Actual Human Trials</title><link>https://biohackhealth.uk/blog/collagen-peptides-human-trials/</link><guid>https://biohackhealth.uk/blog/collagen-peptides-human-trials/</guid><pubDate>Mon, 24 Aug 2026 23:00:00 GMT</pubDate><description>Unusually for this space, the core findings come from controlled trials in people. Effect sizes are modest, and the protocol matters more than the product.</description><category>Research</category></item>
<item><title>GLP-1 Agonists and the Metabolic Flexibility Question</title><link>https://biohackhealth.uk/blog/glp1-metabolic-flexibility/</link><guid>https://biohackhealth.uk/blog/glp1-metabolic-flexibility/</guid><pubDate>Mon, 24 Aug 2026 23:00:00 GMT</pubDate><description>The open question isn't whether these drugs work—it's what they leave behind. Do they improve underlying flexibility or just reduce the load on a broken system?</description><category>Research</category></item>
<item><title>BPC-157: A Deep Preclinical File and an Empty Clinical One</title><link>https://biohackhealth.uk/blog/bpc-157-preclinical-file/</link><guid>https://biohackhealth.uk/blog/bpc-157-preclinical-file/</guid><pubDate>Mon, 24 Aug 2026 23:00:00 GMT</pubDate><description>No completed modern controlled human trial exists. Everything describing efficacy comes from animal models or cell culture. Both of these facts are true at once.</description><category>Research</category></item>
</channel></rss>
